Suchergebnisse - "Schenker, Michael"

PubPharm (78)

1

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study) : an international, randomized, placebo-controlled, phase 3 trial

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Kang, Y. | Ryu, M. | Di Bartolomeo, M. | +15

2

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma : 3-Year Follow-Up of the Phase III CheckMate 649 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Janjigian, Y. | Ajani, J. | Moehler, M. | +23

3

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

enthalten in: Journal for immunotherapy of cancer | 2024

von Carbone, D. | Ciuleanu, T. | Schenker, M. | +23

4

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

enthalten in: Gastric Cancer | 2024

von Kang, Y. | Ryu, M. | Di Bartolomeo, M. | +15

5

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer : Results From the CANOPY-1 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Tan, D. | Felip, E. | de Castro, G. | +20

6

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Moehler, M. | Xiao, H. | Blum, S. | +21

7

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer : the randomized PERLA phase II trial

enthalten in: Nature communications | 2023

von Lim, S. | Peters, S. | Ortega Granados, A. | +13

8

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma

enthalten in: The New England journal of medicine | 2023

von van der Heijden, M. | Sonpavde, G. | Powles, T. | +22

9

Carcinoembryonic Antigen CEA - Prognostic Value in Immediate Post-Operative Mortality in Colorectal Cancer

enthalten in: Current health sciences journal | 2023

von Firut, A. | Scurtu, S. | Schenker, M. | +5

10

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma : The Open-Label, Phase III PIVOT IO 001 Trial Results

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Diab, A. | Gogas, H. | Sandhu, S. | +23

1
2
3
4
5
6
7
8
Nächster »
[8]